Bellevue Group AG Invests $344,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Bellevue Group AG bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,500 shares of the biotechnology company's stock, valued at approximately $344,000.

A number of other hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $30,000. Jones Financial Companies Lllp lifted its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the period. GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $96,000.

Analysts Set New Price Targets

Several equities analysts have commented on ASND shares. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Royal Bank of Canada upped their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Cantor Fitzgerald raised their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Finally, Wedbush boosted their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus price target of $216.07.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded down $8.14 on Friday, reaching $151.25. 598,419 shares of the stock were exchanged, compared to its average volume of 498,116. The stock has a 50 day moving average price of $156.11 and a 200 day moving average price of $141.22. The stock has a market cap of $9.22 billion, a PE ratio of -21.30 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.